Jim Omel, MD

Jim’s advocacy includes work with the NCI Myeloma Steering Committee, FDA, Alliance Cooperative Group (Myeloma and Transplant Committees), Center for International Blood and Marrow Transplant Research (CIBMTR), Moffitt Cancer Center, Fred Hutchinson Cancer Research Center in Seattle, ASCO (CancerLinQ and Bisphosphonates in Myeloma Review Panel), local hospital cancer committee, and of course, his Central Nebraska Myeloma Support Group.

Follow Jim on Twitter

Recollections of the 60th Annual ASH Meeting and Expo

Jim Omel |

ASH is over but its memories are fresh. My strongest impression of the meeting is that multiple myeloma treatment advances continue to be significant at this huge yearly event. Dr. Durie explained there were an amazing 939 abstracts relating to myeloma at ASH this year. At the IMWG (International Myeloma Working Group) meeting, he said […]

Patient Stories and Brian D. Novis Research Grant Awards Reception

Jim Omel |

A highlight every year for IMF Support Group Leaders attending ASH is the Patient Stories and Brian D. Novis Research Grant Awards Reception. Young scientists with meritorious projects are helped in their myeloma research by grants from the IMF. A significant amount of basic and translational knowledge about myeloma the last twenty years has brought […]

Using Minimal Residual Disease (MRD) in Clinical Practice

Jim Omel |

Each year as ASH begins the Blood & Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup meets to improve treatment approaches related to transplantation in multiple myeloma. This group, representing all significant transplantation centers, discussed incorporating minimal residual disease (MRD) testing to better serve patients. These are some of the questions they reviewed.   […]

The Things We Learn at ASH

Jim Omel |

I look forward every year to Annual ASH Meeting, whether I’m attending in person or experiencing it from home via Twitter, blogs, and professional writers. At ASH we learn new advances in treating, evaluating, and living with myeloma. Immunology has become a central focus of recent ASH meetings and #ASH18 #IMFASH18 will be more of […]